Search results for " Ulcerative"

showing 10 items of 158 documents

Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

2000

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…

AdultMalemedicine.medical_specialtyRandomizationPrednisoloneAzathioprinePilot ProjectsMycophenolateGastroenterologyMycophenolic acidInternal medicineAzathioprineMedicineHumansColitisGlucocorticoidsAgedHepatologybusiness.industryChronic ActiveRemission InductionGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseUlcerative colitisSurgeryChronic DiseasePrednisoloneColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

2016

AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician' s global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database. RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the averag…

AdultMalemedicine.medical_specialtyTime FactorsAnti-Inflammatory AgentsObservational StudySeverity of Illness IndexGolimumab03 medical and health sciences0302 clinical medicineGastrointestinal AgentsAdrenal Cortex HormonesInternal medicineHumansMedicineProspective StudiesTumor Necrosis Factor-alphabusiness.industryRemission InductionGastroenterologyAntibodies MonoclonalColonoscopyGeneral MedicineMiddle Agedmedicine.diseaseReal-life resultsUlcerative colitisdigestive system diseasesGolimumabTreatment OutcomeMulticenter studyUlcerative colitisSpain030220 oncology & carcinogenesisColitis UlcerativeDrug Therapy CombinationFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

2017

AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …

AdultMalemedicine.medical_specialtyTime FactorsTumor necrosis factor-inhibitorMultidisciplinary studyObservational StudyInflammatory bowel diseasesInflammatory bowel diseaseWorkflowEnteropathic spondyloarthriti03 medical and health sciences0302 clinical medicineCrohn DiseaseClinimetric assessmentInternal medicineSpondylarthritisTumor necrosis factor-inhibitorsAdalimumabHumansMedicinePatient Reported Outcome MeasuresPatient reported outcomes030203 arthritis & rheumatologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionAdalimumabGastroenterologyInflammatory Bowel DiseasesGeneral MedicineMiddle AgedPatient reported outcomeEnteropathic spondyloarthritisClinimetric assessment; Enteropathic spondyloarthritis; Inflammatory bowel diseases; Multidisciplinary evaluation; Patient reported outcomes; Tumor necrosis factor-inhibitors; GastroenterologyTreatment OutcomeMultidisciplinary evaluationAntirheumatic AgentsCritical PathwaysQuality of LifeColitis UlcerativeFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational stu…

2011

Introduction: About 30-40% of patients with acute severe ulcerative colitis (UC) fail to respond to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an effective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is the best therapeutic choice. Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively since 1994 comparing two historical cohort treated with iv cyclosporine (2 mg/kg) or iv infliximab (5 mg/kg). The main outcome was the colectomy rate at 3 months, 12 months and at the end of the follow-up. Results: A total of 65 patients were included: 35 in the cyclosporine group and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAzathioprineKaplan-Meier EstimateGastroenterologyCohort StudiesRefractoryInternal medicinemedicineHumansColitisColectomyRetrospective StudiesColectomybiologybusiness.industryC-reactive proteinGastroenterologyAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUlcerative colitisInfliximabInfliximabSurgeryLogistic ModelsTreatment OutcomeCyclosporinebiology.proteinColitis UlcerativeFemalebusinessImmunosuppressive AgentsFollow-Up Studiesmedicine.drugJournal of Crohn's and Colitis
researchProduct

Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature

2023

Ménétrier’s disease (MD) is a rare disease of the stomach, characterised by hypertrophic gastric folds leading to protein loss. The association with ulcerative colitis (UC) is rare but has been reported in the literature. We report a case of a 29-year-old male affected by UC with an additional diagnosis of MD 3 years after UC diagnosis. UC was refractory to several treatment lines (thiopurines, infliximab, vedolizumab and ustekinumab), and the patient underwent colectomy. Octreotide was administered for MD normalising blood biochemistry, but it was not effective in inducing endoscopic remission of the stomach. Treatment options in patients with MD and UC are discussed.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentGastroenterologyInflammatory bowel diseaseVedolizumabInternal medicineUstekinumabmedicineHumansGastritis HypertrophicColectomybusiness.industryGeneral Medicinemedicine.diseaseUlcerative colitisInfliximabInfliximabMénétrier's diseaseColitis UlcerativeUstekinumabbusinessRare diseasemedicine.drugdrugs: gastrointestinal system; gastroenterology; inflammatory bowel disease
researchProduct

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.

2003

Timely diagnosis of intraepithelial neoplasias (IN) and colitis-associated colon carcinomas (CRC) is crucially important for the treatment of ulcerative colitis (UC). We performed a randomized, controlled trial to test whether chromoendoscopy (CE) might facilitate early detection of IN and CRC in UC.A total of 263 patients with long-standing UC (or=8 years) were screened for potential inclusion in the study, 165 of whom were randomized at a 1:1 ratio to undergo conventional colonoscopy or colonoscopy with CE using 0.1% methylene blue. Five mucosal biopsy specimens were taken every 10 cm between the rectum and cecum. Circumscript lesions in the colon were evaluated according to a modified pi…

Adultmedicine.medical_specialtyColorectal cancerBiopsyRectumColonoscopyPilot ProjectsGastroenterologySeverity of Illness IndexChromoendoscopyPredictive Value of TestsInternal medicineBiopsymedicineHumansProspective StudiesColitisColoring AgentsAgedIntraepithelial neoplasiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyMiddle Agedmedicine.diseaseUlcerative colitisMethylene Bluemedicine.anatomical_structureColonic NeoplasmsColitis UlcerativebusinessCarcinoma in SituGastroenterology
researchProduct

Chromoscopy-Guided Endomicroscopy Increases the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative Colitis

2007

Background & Aims: Because of the large number of biopsy specimens, surveillance colonoscopy in ulcerative colitis (UC) is currently time consuming and significant flat lesions still may be missed. In this study we assessed the value of combined chromoscopy and endomicroscopy for the diagnosis of intraepithelial neoplasias in a randomized controlled trial. Methods: A total of 161 patients with long-term UC in clinical remission were randomized at a 1:1 ratio to undergo conventional colonoscopy or chromoscopy with endomicroscopy. Eight patients were excluded because of insufficient bowel preparation. In the conventional colonoscopic group (n = 73), random biopsy examinations and targeted bio…

Adultmedicine.medical_specialtyTime FactorsColonBiopsyVideo RecordingSensitivity and SpecificitySeverity of Illness IndexTargeted biopsyGastroenterologyChromoendoscopyPredictive Value of TestsInternal medicineBiopsyEndomicroscopyHumansMedicineIntestinal MucosaColitisColoring AgentsAgedFluorescent DyesIntraepithelial neoplasiaMicroscopy ConfocalHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyMiddle Agedmedicine.diseaseUlcerative colitisMethylene BluePredictive value of testsColonic NeoplasmsColitis UlcerativeFluoresceinRadiologybusinessCarcinoma in SituGastroenterology
researchProduct

Pitfall prayer marks: Recognition and appropriate treatment: A case report and review of literature.

2019

Prayer marks are asymptomatic callosities resulting from repeated, extended pressure, and friction exerted on bony prominences when praying on hard ground. A 41-year-old woman with ulcerative colitis treated with infliximab was referred to our clinic due to skin changes on her feet that were suspected to be drug eruptions. The patient presented several asymptomatic, hyperpigmented, and hyperkeratotic plaques over the lateral malleoli suggesting that the lesions had a mechanical cause. Further exploration revealed that the patient, a practicing Muslim, prays in a sitting position called "Julus" several times a day. After color marking, the lesions over the lateral feet left a precise imprint…

Adultmedicine.medical_specialtymedia_common.quotation_subjectDermatologyIslam030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineHyperpigmentationMedicineHumansmedia_commonSkinCallositybusiness.industryFootGeneral surgeryGeneral MedicinehumanitiesPrayerInfliximab030220 oncology & carcinogenesisColitis UlcerativeFemaleHyperkeratotic plaquesDrug EruptionsbusinessSkin lesionDermatologic therapyREFERENCES
researchProduct

Auto-immune haemolytic anaemia in ulcerative colitis: report of three cases.

1994

Autoimmune diseaseHemolytic anemiaAdultMalebusiness.industryHematologyGeneral Medicinemedicine.diseaseAuto immuneUlcerative colitisAdrenal Cortex HormonesImmunopathologyImmunologymedicineSplenectomyHumansColitis UlcerativeFemaleAnemia Hemolytic AutoimmuneYoung adultComplicationbusinessColectomyImmunosuppressive AgentsActa haematologica
researchProduct

Analysis of the Association between Fatigue and the Plasma Lipidomic Profile of Inflammatory Bowel Disease Patients

2020

Inflammatory bowel disease (IBD) is a chronic, relapsing noninfectious inflammatory condition of the intestinal tract with two main phenotypes, ulcerative colitis (UC) and Crohn's disease (CD), and globally increasing incidence and prevalence. Nearly 80% of the IBD patients with active disease and 50% of those with inactive disease suffer fatigue with significant impairment of their quality of life. Fatigue has been associated with multiple factors in IBD patients but, in most cases, no direct cause can be identified, and risk factors in clinically quiescent IBD are contradictory. Furthermore, as the assessment of fatigue is subjective, there is an unmet clinical need for fatigue biomarkers…

BioquímicaBiologiamedicine.medical_specialtyDiseaseBiochemistryInflammatory bowel diseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineLipidomicsmedicineHumansFatigue030304 developmental biology0303 health sciencesCrohn's diseasebusiness.industryIncidence (epidemiology)General ChemistryInflammatory Bowel Diseasesmedicine.diseaseSphingolipidUlcerative colitis3. Good health030220 oncology & carcinogenesisLipidomicsQuality of LifeColitis UlcerativebusinessSphingomyelinJournal of Proteome Research
researchProduct